Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Breast Neoplasms 1

Interventions

Dexamethasone 45Bortezomib 21Lenalidomide 19Cyclophosphamide 19daratumumab 16Calcium Dobesilate 13Thalidomide 12Melphalan 11carfilzomib 9Prednisone 7pomalidomide 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6Filgrastim 5dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Vincristine 4isatuximab 3Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2Steroids 2Radiotherapy 2Microarray Analysis 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Multiple Myeloma × valspodar × Clear all
NCT00002878 2023-06-15

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Eastern Cooperative Oncology Group

Phase 3 Completed
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡